Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Up 826.1% in February

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 1,226,671 shares, a growth of 826.1% from the January 29th total of 132,462 shares. Approximately 19.6% of the company’s shares are sold short. Based on an average trading volume of 6,360,187 shares, the short-interest ratio is presently 0.2 days. Based on an average trading volume of 6,360,187 shares, the short-interest ratio is presently 0.2 days. Approximately 19.6% of the company’s shares are sold short.

Biorestorative Therapies Stock Performance

BRTX stock traded down $0.04 during midday trading on Wednesday, hitting $0.23. 14,230,726 shares of the company’s stock were exchanged, compared to its average volume of 8,840,344. Biorestorative Therapies has a one year low of $0.19 and a one year high of $2.28. The company has a market cap of $2.04 million, a PE ratio of -0.15 and a beta of 0.39. The stock’s fifty day moving average price is $0.96 and its 200-day moving average price is $1.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Biorestorative Therapies

Several institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in Biorestorative Therapies during the 3rd quarter worth approximately $152,000. DRW Securities LLC acquired a new position in shares of Biorestorative Therapies in the fourth quarter valued at approximately $55,000. Finally, Virtu Financial LLC boosted its holdings in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares during the period. 69.38% of the stock is currently owned by institutional investors and hedge funds.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.